PMC-309

N/A

Report date: 2024/01/02 20:03:52

Base Information

Drug NamePMC-309
Drug Alias NamePMC-309
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionV-domain Ig suppressor of T-cell activation inhibitorsAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulants
TargetsV-domain Ig suppressor of T-cell activation
Therapy Area/IndicationsSolid tumoursNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesPharmabcine
China Registration ClassN/A

Develop Information

Active CompaniesAprogenPharmabcine
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A